MarginsXMarginsX
Home › Markets › Health Care › NKTX

Nkarta Inc. (NKTX)

NKTX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.21
+1.68% on the day
Market cap
$86.8M
Micro cap
Revenue · 2025
$0
Prior year not contiguous
Net income · 2025
-$104.1M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1787400/000178740026000006/0001787400-26-000006-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerNKTX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2020
SEC CIK0001787400
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$0
Net income-$104.1M
Operating income-$122.0M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growthNo prior-year revenue to compare
Cash$39.6M
Total assets$404.2M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
5.8 months
$48.4M cash at September 30, 2026
Share count, 1 year
+1.0%
2025-11-05 to 2026-11-02 · +46.1% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$70K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$48.4M cash; operating cash flow -$25.0M a quarter.Report 2026-09-30
Shares outstanding71,704,404 (2026-11-02); 71,029,512 a year earlier; 49,072,342 three years earlier.Cover page 2026-11-02
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-04-03
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Mateo, California, United StatesPCAOB Form AP 2026-04-06
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $70K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$33.3M-$25.8M$48.4MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q2 2026
2026-06-30
Not filed-$40.4M-$24.2M$25.0MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q1 2026
2026-03-31
Not filed-$27.8M-$28.2M$27.4MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q4 2025
2025-12-31
Not filed-$27.4M-$21.6M$39.6MNo debt tags$010-K 2026-03-25
Q3 2025
2025-09-30
Not filed-$21.7M-$18.7M$60.1MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q2 2025
2025-06-30
Not filed-$23.0M-$18.8M$53.4MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q1 2025
2025-03-31
Not filed-$32.0M-$29.6M$52.6MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q4 2024
2024-12-31
Not filed-$25.9M-$24.8M$27.9MNo debt tags$010-K 2026-03-25

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-04-03
Latest annual report10-K2026-03-25
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-09
Latest proxyDEFA14A2026-04-23

Source: SEC EDGAR submissions feed, 440 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-31.2%
1 month-43.3%
3 months-48.3%
Year to date-35.7%
1 year-36.7%
From 52-week high-67.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
GNLXGenelux Corporation$1.92+2.95%$86.9M
KZIAKazia Therapeutics Limited$5.60-15.41%$87.1M
RLYBRallybio Corporation$15.43-1.88%$86.4M
HURATuHURA Biosciences Inc.$1.33-4.32%$87.5M
ANIXAnixa Biosciences Inc.$2.55-2.67%$88.6M
PMVPPMV Pharmaceuticals Inc.$1.19-6.30%$89.9M
RTSNRetension Pharmaceuticals Inc.$11.46-6.60%$90.3M
PLYXPolaryx Therapeutics Inc.$1.67-6.99%$83.2M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier